Back

Why do clinicians withhold anticoagulation in patients with atrial fibrillation and CHA2DS2VASc score of 2 or higher?

27 August 2018 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 4 - Atrial fibrillation - Stroke prevention Oral Anticoagulation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Assistant Professor Deborah Michelle Siegal

McMaster University, Hamilton (Canada)

27 More presentations in this session

Presentation thumbnail
Professor P. Penson (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Doctor I. Cavallari (Rome, IT)
Abstract Slides
Presentation thumbnail
Doctor A. Jhand (Omaha, US)
Abstract Slides
Presentation thumbnail
Doctor A. Thandra (Omaha, US)
Abstract Slides
Presentation thumbnail
Doctor S. Pokorney (Durham, US)

Access the full session

Session thumbnail
Poster Session 4 - Atrial fibrillation - Stroke prevention

The Event

Event poster

ESC Congress 2018

27 August 2018 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Exploring the feasibility of discontinuing oral anticoagulant therapy in post-ablation atrial fibrillation patients with low stroke risk: a conceptual inquiry
1 April 2025
thumbnail
Webinar
Anticoagulation challenges in older subjects with multimorbidity
25 July 2023
thumbnail
Congress Presentation
Does Atrial Fibrillation adds discriminatory value for patients with advanced heart failure with reduced ejection fraction?
29 June 2021
thumbnail
Congress Presentation
Inappropriate use of anti-thrombotic therapy in patients with atrial fibrillation in a general cardiology outpatient clinic versus a multidisciplinary heart failure team
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources